Immunogenicity, safety, and tolerability of a recombinant measles-vectored Lassa fever vaccine: a randomised, placebo-controlled, first-in-human trial-Reference-Cited by-同舟云学术

Immunogenicity, safety, and tolerability of a recombinant measles-vectored Lassa fever vaccine: a randomised, placebo-controlled, first-in-human trial

Published:2023-04 Issue:10384 Volume:401 Page:1267-1276
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Tschismarov Roland,Van Damme Pierre,Germain Clara,De Coster Ilse,Mateo Mathieu,Reynard Stephanie,Journeaux Alexandra,Tomberger Yvonne,Withanage Kanchanamala,Haslwanter Denise,Terler Katherine,Schrauf Sabrina,Müllner Matthias,Tauber Erich,Ramsauer Katrin,Baize Sylvain

Publisher

Elsevier BV

Subject

General Medicine

Reference29 articles.

1. Clinical characterization of Lassa fever: a systematic review of clinical reports and research to inform clinical trial design;Merson;PLoS Negl Trop Dis,2021

2. Lassa fever in Benin: description of the 2014 and 2016 epidemics and genetic characterization of a new Lassa virus;Yadouleton;Emerg Microbes Infect,2020

3. Risk maps of Lassa fever in west Africa;Fichet-Calvet;PLoS Negl Trop Dis,2009

4. Pathogenicity and virulence mechanisms of Lassa virus and its animal modeling, diagnostic, prophylactic, and therapeutic developments;Murphy;Virulence,2021

5. Inter-lineage variation of Lassa virus glycoprotein epitopes: a challenge to Lassa virus vaccine development;Ibukun;Viruses,2020

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Health and economic impacts of Lassa vaccination campaigns in West Africa;Nature Medicine;2024-08-28

2. Lassa Fever: Critical Review and Prospects for Control;Tropical Medicine and Infectious Disease;2024-08-14

3. Modelling Lassa virus dynamics in West African Mastomys natalensis and the impact of human activities;Journal of The Royal Society Interface;2024-07

4. Lassa fever research priorities: towards effective medical countermeasures by the end of the decade;The Lancet Infectious Diseases;2024-07

5. A measles-vectored vaccine candidate expressing prefusion-stabilized SARS-CoV-2 spike protein brought to phase I/II clinical trials: candidate selection in a preclinical murine model;Journal of Virology;2024-05-14